ECUADOR

CERVICAL CANCER PROFILE

Morbidity and Mortality

- Crude cervical cancer incidence per 100,000 women (2020): 17.4
- Age-standardized cervical cancer incidence per 100,000 women (2020): 16
- Cumulative risk of cervical cancer, ages 0-74 (2020): 1.7%
- Cervical cancer deaths (2019): 840
- Cervical cancer mortality-to-incidence ratio (2020): 0.53
- Population-based cancer registry exists (2021): Yes

Primary Prevention

- HPV vaccination programme coverage among girls (2020):
  - Programme coverage: 75%
  - Coverage by age 15: 75%
  - Among girls turning 15 years old in 2020, 7 in 10 received their final HPV vaccination dose
- HPV vaccination programme (2020):
  - HPV included in national vaccination programme: Yes
  - Scale of vaccination programme: National
  - Year of introduction: 2014
  - Primary target cohort: 9 years
- Related risk factors:
  - Tobacco use prevalence, women aged 15+ years (2020): 3%
  - Condom use at last high-risk sex (-): ND
  - HIV incidence per 1000, women aged 15+ years (2020): 0.1

Secondary Prevention

- National screening programme for cervical cancer exists (2021): Yes
- Primary screening test used (2021): Cytology (HPV test from 30 years)
- Target age range of programme (2021): 21-65 years
- Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): Yes
- Clearly defined referral system exists from primary care to secondary and tertiary care (2021): Yes

Treatment and Supportive Care

- National guidelines on cervical cancer management exist (2021): No
- Cancer diagnosis and treatment services generally available (2021):
  - Cancer centre or cancer department at tertiary level: Yes
  - Pathology services (laboratories): Yes
  - Cancer surgery: Yes
  - Chemotherapy: Yes
  - Radiation therapy: Yes
- Palliative care for patients with NCDs in the public health system generally available (2021):
  - In primary health care facilities: Yes
  - In community or home-based care: Yes

WHO Cervical Cancer Elimination Strategy Targets for 2030

- 90% of girls fully vaccinated with the HPV vaccine by the age of 15
- 70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
- 90% of women identified with cervical disease receive treatment

World Health Organization - Cervical Cancer Country Profiles, 2021

ND = data not available

* Programme coverage: % of national target population (among 9-14-year-old girls)
† Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

See Explanatory Notes for indicator descriptions.